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CASE PRESENTATION
A 26-year-old Caucasian man with a history of viral
myocarditis and subsequent heart transplant at age 13
underwent a kidney biopsy for rapidly deteriorating renal
function. The patient’s baseline serum creatinine was
2.2–3.0 mg/dl (194–264 mmol/l) with 3þ albuminuria by
dipstick, but had recently increased to 4.8 mg/dl
(422 mmol/l) over a 5-month period. His
immunosuppressive regimen included azathioprine,
prednisone, and cyclosporine (CsA); the latter was
changed to sirolimus 6 months before presentation
without improvement in renal function. Treatment with
sirolimus led to the development of acne, which was
treated with a 5-month course of cephalexin. Empiric
therapy with prednisone for presumed allergic interstitial
nephritis was ineffective after 2 weeks of therapy. Past
history was otherwise remarkable for hypertension and
hyperlipidemia. Physical examination revealed a
well-appearing man. His blood pressure was 156/96,
heart rate was 92, and he was afebrile. His jugular
venous pressure was not elevated and there was trace
peripheral edema. The remainder of the examination
was unremarkable. Laboratory values are shown in
Table 1. The serological work-up for a secondary cause
for his nephrotic-range proteinuria was negative. He
subsequently underwent renal biopsy to guide therapy.
RENAL BIOPSY FINDINGS
Light microscopic examination revealed extensive cortical
atrophy, with focal glomerular and tubular changes present
suggestive of a collapsing glomerulopathy and possibly
secondary to superimposed structural and functional adapta-
tions. Extensive glomerular sclerosis, tubular atrophy, and
interstitial fibrosis were present affecting approximately 70%
of the kidney parenchyma, in addition to prominent arterial
sclerosis and arteriolar hyalinosis. Immunofluorescence
revealed no significant immune deposits in the glomeruli.
Segmental, irregular granular deposition of IgM and C3 was
present in the mesangial areas, and the tubules contained
reabsorbed proteins (albumin, IgG, and C3) in the form of
diffuse cytoplasmic granules. Electron microscopy showed
extensive injury of the visceral epithelium characterized by
focal effacement of foot processes and prominent vacuoliza-
tion of the epithelial cell cytoplasm. Focal and segmental
collapse of capillaries with entrapment of hyaline was noted.
DIAGNOSIS
Collapsing glomerulopathy with extensive cortical atrophy and
focal global and segmental glomerulosclerosis. Arterial sclerosis
and arteriolar hyalinosis, possibly related to CsA therapy.
CLINICAL FOLLOW-UP
After the diagnosis of collapsing glomerulopathy, the patient
was started on captopril 6.25 mg po t.i.d., which was
subsequently discontinued as his serum creatinine increased
from 4.8 mg/dl (424 mmol/l) to 7.3 mg/dl (645 mmol/l) over
a 6-day period. He progressed to end-stage renal disease
(ESRD) over the next 7 months and initiated peritoneal
dialysis before undergoing living-unrelated renal transplanta-
tion 12 months after renal biopsy. At last follow-up, 6 months
after renal transplantation, the serum creatinine was
1.4 mg/dl (124 mmol/l) with no proteinuria on urinalysis
(Figure 1).
DISCUSSION
Collapsing glomerulopathy (CG) is a morphologic variant of
focal segmental glomerulosclerosis (FSGS), characterized by
segmental and global collapse of the glomerular capillaries,
marked hypertrophy and hyperplasia of podocytes, and
severe tubulointerstitial disease,1 and presents with heavy
proteinuria, renal insufficiency, and rapid progression to
ESRD. 2 The cause of this podocyte disorder is unknown, and
CG has been reported as an immunological, viral, toxin-
related or inherited disease with similar renal survival
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outcomes,3 suggesting that the characteristic renal pathology
may simply be the final common pathway to glomerular
obsolescence. The patient’s previous exposure to parvovirus
B19 may have contributed to the development of CG;4
although this virus is also commonly found in the general
population. Long-term CsA use has been associated with
FSGS and, at least in renal transplant patients,5 the
development of CG. In the absence of other secondary
causes of CG in our patient, we concluded that the renal
pathology primarily reflected longstanding damage consis-
tent with calcineurin-inhibitor nephrotoxicity. Clearly, how-
ever, we could not rule out the possibility that an undetected
viral infection was playing a causative role or that this was
simply a primary FSGS, although given the tendency of
idiopathic FSGS to recur post-renal transplant, the latter
diagnosis is less likely.6
CYCLOSPORINE NEPHROTOXICITY AFTER CARDIAC
TRANSPLANT
CsA is considered to be the main cause of renal dysfunction
post-cardiac transplant. Features of CsA-associated nephro-
toxicity are outlined in Table 2. Irreversible CsA nephrotoxi-
city has been reported after heart, liver, lung, pancreas, and
bone marrow transplantation as well as in patients with
uveitis, diabetes mellitus, rheumatoid arthritis, and psori-
asis.7 In the heart transplant population, chronic CsA toxicity
is responsible for a 10% prevalence of ESRD occurring by 10
years post-heart transplantation,8 whereas results are even
more dismal after heart–lung transplantation, with a 10%
prevalence of ESRD within 5 years.9 After heart transplanta-
tion, there is loss of renal function within 3–6 months
which is both CsA dose-dependent10 and progressive.11
CsA-induced nephrotoxicity is characterized by an initially
reversible decline in glomerular filtration rate (GFR), which
is likely caused by a direct drug-induced afferent arteriolar
vasoconstriction, leading to renal hypoperfusion and salt
and water retention associated with hypertension.7 The
mechanisms underlying renal vasoconstriction and hypo-
filtration are unclear, but abnormalities in endogenous
Table 1 | Laboratory values
Serum/blood (reference range)
Blood urea nitrogen (mg/dl) 64 (7–22) (29 mmol/l
(3.2–8.9))
Creatinine (mg/dl) 4.8 (0.6–1.3)
(424 mmol/l (62–115))
Urine (reference range)
Urinalysis pH 6, specific gravity 1.020,
1+blood, 3+protein,
all else negative
Microscopy Nondysmorphic red
blood cells, white blood
cells, and hyaline casts
Protein/creatinine (mg/mg) 4.59 (o0.15)
Serologic tests (reference range)
Hepatitis B antigen Negative (negative)
Hepatitis B and C antibodies Negative (negative)
HIV antibody Negative (negative)
ANA Negative (negative)
Complement
CH 50 (U/ml) 226 (150–250)
C3 (mg/dl) 116 (90–180)
C4 (mg/dl) 33 (10–40)
ANCA Negative (negative)
Anti-glomerular basement
membrane antibody
Negative (negative)
Parvovirus B19 IgG 3.11 (positive41.10)
Parvovirus B19 IgM 0.11 (negativeo0.9)
ANCA, anti-neutrophil cytoplasmic antibody.
Figure 1 | Renal histology (light microscopy). (a) The cortex reveals extensive tubular atrophy, marked sclerosis of the arterial walls and
hyaline degeneration of arterioles (arrows). Two glomeruli reveal global sclerosis, and one glomerulus in the upper right corner shows a
collapsing lesion. There is also widespread tubular atrophy present (periodic acid-Schiff stain). (b) The glomerular tuft shows extensive collapse
of capillaries, early hyaline entrapment, and prominence and crowding of glomerular epithelial cells (periodic acid-Schiff stain). (c) Three
tubules to the left side reveal microcystic changes and contain weak periodic acid-Schiff -positive cast material. Two proximal tubules
(right side of the photomicrograph) contain prominent protein reabsorption granules. The interstitium is expanded by connective tissue
and mild inflammation (periodic acid-Schiff stain).
Table 2 | Clinical and pathological spectrum of CsA-associated
nephrotoxicity
Sodium retention and edema
Electrolyte disorders (hyperkalemia, hypomagnesemia, hyperchloremic
metabolic acidosis, hyperuricemia)
Hypertension
Proteinuria (nonnephrotic or nephrotic range)
Acute reversible, chronic nonprogressive, and chronic progressive
decrease in GFR
ESRD
Acute thrombotic microangiopathy
Isometric tubular vacuolization
Hyaline arteriolopathy
Interstitial fibrosis (typically patchy or ‘striped’)
Segmental to global glomerulosclerosis with hypertrophy of remaining
glomeruli
CsA, cyclosporine; ESRD, end-stage renal disease; GFR, glomerular filtration rate.
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vasoconstrictor and vasodilator mechanisms may be
responsible.7
Predictive factors in the development of cyclosporine
nephrotoxicity
Identification of risk factors in the development of CsA
nephrotoxicity has proven to be difficult, and somewhat
controversial (Table 3). There appears to be general
agreement that physicians should prescribe the lowest
possible dose that still provides therapeutic benefit, although
the optimal dosing regimen remains unclear. High CsA levels
early in the post-transplant period may contribute kidney
failure: in a study of pediatric cardiac transplant recipients,
Hornung et al.12 demonstrated that decline in renal function
after heart transplantation correlates with early CsA ex-
posure, and that renal dysfunction persisted even after
reduction in CsA dose. However, two large studies by Zietse
et al.11 and Lindelow et al.13 demonstrated no relationship
between the CsA concentration and the decline in renal
function measured as the slope of serum creatinine as a
function of time or by serial GFR measurements. A
case–control study by van Gelder et al.14 showed that CsA
doses and trough levels in the 24 heart transplant patients
who developed ESRD were not different from the patients
maintaining stable renal function, suggesting that CsA
nephrotoxicity is the result of an individually determined
susceptibility to the calcineurin inhibitor. Certainly, some of
the variability in interindividual CsA side-effect profile
disposition has been attributed to differences in the
expression of the metabolizing enzymes cytochrome P450
3A4 and 3A5, and in the expression of the drug transporter
P-glycoprotein encoded by the ABCB1 gene.15 In addition,
the method of CsA administration is likely relevant because
GFR has been reported to improve if CsA is given once rather
than twice daily in stable heart transplant patients.16
Age plays a controversial role in the development of renal
failure after heart transplantation, with some studies showing
that kidney disease was not limited to elderly patients with
ischemic heart disease, but also occurred in young patients
having dilated cardiomyopathy,11,14 whereas others show age
to be an independent predictor of post-cardiac transplant
renal dysfunction.13,17,18 Male gender may be protective,19
and it is postulated that this is secondary to the increased
nephron endowment in men compared to women. Blood
pressure has been negatively correlated with rate of GFR
decrease in cardiac transplant recipients.18,20 Although some
groups have reported no correlation between preoperative
renal function and post-transplant risk of chronic kidney
disease,13 others have found that an impaired preoperative
GFR increased the risk of renal failure.18,19 Risk factors for
cardiovascular disease, such as hyperlipidemia21 and dia-
betes,18,19 have been reported to contribute to progression of
renal dysfunction in this population, although it is difficult to
know if the presence of these risk factors accelerates
progression of CsA nephrotoxicity specifically, as most
studies do not include renal biopsy data. Retinol-binding
protein is a small globular protein that is filtered by glomeruli
and almost totally reabsorbed by the proximal tubules.
Urinary excretion increases in the presence of proximal
tubule dysfunction.22 CsA is associated with irreversible
tubular injury, and Caˆmara et al.23 found that high urinary
retinol-binding protein concentrations predicted those heart
transplant recipients who were at highest risk of progressive
renal failure, suggesting that such patients may benefit from a
reduction in CsA dose to limit renal damage.
Renal histology
Renal histology from native kidneys exposed to long-term
CsA shows a variable amount of both global and segmental
glomerular sclerosis with a tendency for remaining functional
glomeruli to be larger, consistent with glomerular hyperfil-
tration and increasing proteinuria.10,24 In contrast to native
kidneys, the glomerular collapse in renal allografts is
associated with obliterative vascular changes with a zonal
distribution, possibly related to uneven distribution of the
blood supply.25 These changes are possibly secondary to
progressive arteriolar vasculopathy leading to glomerular
ischemia and tubular atrophy, changes which are seen as early
as after 2 years of low-dose CsA therapy.24 The pattern of loss
initially results in a characteristic appearance of striped
tubular atrophy and fibrosis which begins in the medulla and
progresses to the medullary rays of the cortex. In a study
examining the renal pathology of heart–lung transplant
recipients, changes were noted in both the endothelial and
vascular smooth muscle cells.26 Interestingly, although
cardiac transplant patients treated with low doses of CsA
had slightly lower mean serum creatinine concentrations,
similar pathological changes were seen on renal biopsy when
compared to those treated with higher doses,27 suggesting
that low versus high dosage of CsA confers only marginal
protection against this serious microvascular injury.
Pathogenesis
The pathophysiology of CsA nephrotoxicity is unclear. There
appears to be dissociation between progressive tubulointer-
Table 3 | Potential risk factors for development of CsA
nephrotoxicity
Risk factor
Presence or absence of
risk factor in current case
Older age at time of transplant 
Ischemic cardiomyopathy in native heart 
Female gender 
Elevated CsA trough levels in early
post-transplant period

Hypertension +
Preoperative renal dysfunction 
Diabetes mellitus 
Hyperlipidemia +
No calcium channel blocker use +
Urinary retinol-binding protein 40.4 mg/l Unknown
Cytochrome P450 3A4 and 3A5, drug
transporter P-glycoprotein expression
Unknown
CsA, cyclosporine.
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stitial and arteriolar disease and renal function with use of
CsA. In a study of uninephrectomized rats on either low- or
high-salt diets treated with CsA or placebo, Elzinga et al.28
found that although GFR was similarly depressed in CsA-
treated animals on either diet, tubulointerstitial injury was
largely confined to salt-depleted CsA-treated rats. Long-term
CsA treatment reduces the salinity/tonicity of the renal
medullary interstitium as a result of inhibition of active
sodium transporters, leading to downregulation of tonicity-
responsive enhancer binding proteins, which protect the
renal medulla from the deleterious effects of hyperosmol-
ality;29 it is thus plausible that salt deficiency accelerates this
process. In contrast, Mervaala et al.30 reported a detrimental
interaction between increased sodium intake and CsA
treatment in spontaneously hypertensive rats. Interestingly,
both the models of high-sodium intake and extreme
salt deficiency are associated with activation of the renin-
angiotensin system.28,30 Animal models of CsA nephrotoxicity
have shown that blockade of the renin-angiotensin system
protects the kidneys from morphological vascular and
tubulointerstitial injury, but without any effect on the decline
of GFR,31 whereas endothelin antagonism prevented the
decrease in GFR without protecting against morphological
injury.32 Certainly, rat models exposed to CsA have demon-
strated increased amounts of renin in the juxtaglomerular
apparatus and in hilar arterioles, with increased expression of
AT1 receptors.33 These reports suggest that angiotensin II,
but not endothelin, is involved in the development of
CsA-induced renal fibrosis. Calcineurin-inhibitor-induced
renal vasoconstriction and chronic ischemia are also asso-
ciated with upregulated intrarenal expression of the
transforming growth factor-b1 in a dose-dependent manner,
which is known to cause irreversible glomerulosclerosis
and tubulointerstitial fibrosis.34
Although the use of ACE inhibitors has not been shown to
date to impact long-term renal function in cardiac transplant
recipients,13 there are reports of calcium channel blockers
having a favorable effect on post-heart transplant renal
function.35 Of note, there is evidence that use of tacrolimus, a
newer calcineurin inhibitor (CNI) with similar pharmacolo-
gic characteristics as CsA, may have a better side-effect profile
with respect to renal function compared to CsA.36
STRATEGIES TO PREVENT CYCLOSPORINE NEPHROTOXICITY
In terms of strategies to reduce the risk of CsA-induced
nephrotoxicity, it is generally agreed that close monitoring of
CsA levels is imperative in limiting the degree of kidney
damage. As there are numerous drugs affecting the metabolism
of CsA, the initiation or withdrawal of new medications
should be followed by careful follow-up of CsA levels. CNI-free
immunosuppressive regimens in cardiac transplantation are
currently being explored, and newer agents, such as the targets
of rapamycin protein inhibitors sirolimus and everolimus,
may play a significant role in care of the heart transplant
patient.37 However, caution should be exercised with the use of
sirolimus in the treatment of FSGS, as it been associated with
nephrotoxicity and significant increases in proteinuria; with-
drawal of the drug appears to reverse the proteinuria.38
Attempts to prevent renal dysfunction should occur at an early
stage post-transplant; therapy may include calcium channel
blockers and probably renin-angiotensin system blockade,
prevention of rejection episodes, avoidance of nephrotoxins,
and treatment of risk factors for kidney disease, such as
diabetes mellitus and hypertension.
CONCLUSION
Nephrologists caring for patients with cardiac transplants
should be aware of the nephrotoxic effects of CsA, as long-
term renal failure is a major contributor to poor prognosis
after heart transplantation, with calcineurin-inhibitor ne-
phrotoxicity being the leading pathogenic cause of renal
impairment. There is unfortunately no universally accepted
accurate marker or predictor of the development of kidney
disease in patients exposed to CsA, although there is
increased interest in the impact of genetic polymorphisms
and hence individual susceptibility to CsA-associated ne-
phrotoxicity. The literature suggests that an immunosup-
pressive regimen that lowers or even avoids calcineurin
inhibitors with the addition of new anti-rejection agents such
as mycophenolate mofetil or sirolimus may be of benefit,
although this must be balanced with the risk of rejection and
possible worsening of nephrotoxicity, outlining the need for a
close clinical relationship between the cardiologist and the
nephrologist caring for the heart transplant patient.
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